Mitraclip Secondary Mr denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for mitraclip secondary mr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied MitraClip for Secondary Mitral Regurgitation as Duplicate Therapy

A duplicate-therapy denial means BCBS determined that another treatment already authorized or in use provides equivalent clinical benefit to the MitraClip transcatheter edge-to-edge repair (TEER) procedure. For secondary (functional) mitral regurgitation, this denial often arises when the plan argues that optimal guideline-directed medical therapy (GDMT) or cardiac resynchronization therapy (CRT) — if already prescribed — constitutes sufficient treatment and that MitraClip adds no distinct benefit over what is currently in place.

## Why This Denial Is Appealable

Secondary MR is a mechanically distinct problem from primary MR and responds differently to each intervention. MitraClip addresses the structural valve leak directly, whereas GDMT and CRT target the underlying cardiomyopathy. Your cardiologist or heart failure specialist can document that these therapies serve different physiologic goals and that your clinical profile — after optimization of all existing therapies — still demonstrates persistent severe regurgitation with functional impairment. That distinction is the foundation of a strong appeal.

## Federal Appeal Framework

You have layered rights: - Internal appeal: Submit within the plan's stated deadline (typically 180 days from denial notice). The plan must decide within 30 days for pre-service requests or 60 days for post-service claims. - External review (ACA §2719 / ERISA §503): If the internal appeal is upheld, you may request independent external review. Under federal rules, you generally have four months from the final internal denial to request external review. An independent organization reviews whether the denial was consistent with generally accepted standards of care. - Expedited review: If delay would seriously jeopardize your health, request expedited external review — a decision is typically required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Echocardiogram or cardiac imaging reports confirming secondary (functional) MR, its severity grading, and the underlying cardiomyopathy etiology. 2. GDMT optimization record: A detailed medication history showing all heart failure therapies trialed, current doses, duration, and your response (or lack of meaningful improvement in MR severity). 3. CRT documentation (if applicable): Evidence that CRT was considered, trialed, or is contraindicated, with outcome data. 4. Functional status: NYHA class documentation, six-minute walk test results, or quality-of-life assessments from your chart. 5. Prescriber letter: A medical-necessity letter from your interventional cardiologist or heart failure team explaining why MitraClip addresses a mechanically distinct target not covered by existing therapies.

## Criteria-Mapping Structure

Request BCBS's published medical policy for transcatheter mitral valve repair and the FDA-approved labeling for MitraClip. For each requirement listed:

| Policy / Label Requirement | Chart Evidence Addressing It | |---|---| | Severity threshold for MR | Imaging report date + grading statement | | GDMT optimization documented | Medication reconciliation + cardiology notes | | Functional class criteria | Most recent NYHA documentation | | Heart team evaluation | Multidisciplinary team note or referral record | | Distinct-from-existing-therapy rationale | Prescriber letter paragraph |

Present each row in your appeal letter so the reviewer sees point-by-point that your case satisfies every stated criterion and that MitraClip is not duplicative but mechanically complementary.